Exploring how macrophages affect fat metabolism in obesity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the role of transcription factor EB (TFEB) in adipose tissue macrophages and its impact on metabolic function in individuals with obesity compared to lean individuals. Participants will undergo screening, body composition imaging, and tissue biopsies, followed by a weight loss intervention for those with obesity. The study aims to understand differences in lipid metabolism between metabolically abnormal obesity and lean individuals.

Why it matters

Who can join: the full rules

Inclusion Criteria :

* age: ≥18 but ≤70 years
* not pregnant or breastfeeding
* weight stable and sedentary before enrollment
* no use tobacco products, excessive amounts of alcohol, or dietary supplements, or medications known to or suspected to affect glucose and lipid metabolism (aside from certain medications used to treat diabetes in the metabolically abnormal obesity \[MAO\]-Type 2 Diabetes group)
* no evidence of significant organ system dysfunction or disease (e.g. chronic severe kidney disease, cancer)
* participants must fulfil all of the following group-specific inclusion criteria below:

Lean group:

* Body mass index (BMI) ≥18.5 but \<25.0 kg/m2
* Intrahepatic triglyceride (IHTG) content \<5%
* fasting blood glucose concentration: \<100 mg/dl
* blood glucose concentration 2 h after a 75 g oral glucose challenge: \<140 mg/dl
* Hemoglobin A1C (HbA1c) \<5.7 %

Metabolically normal obesity (MNO) group:

* BMI ≥30.0 but \<45.0 kg/m2
* IHTG content \<5%
* fasting blood glucose concentration: \<100 mg/dl
* blood glucose concentration 2 h after a 75 g oral glucose challenge: \<140 mg/dl
* HbA1c \<5.7 %

Metabolically abnormal obesity (MAO)-insulin resistance and non-alcoholic fatty liver disease (NAFLD) group:

* BMI ≥30.0 but \<45.0 kg/m2
* IHTG content \>7.5%
* fasting blood glucose concentration: ≥100 but \<126 mg/dl
* blood glucose concentration 2 h after a 75 g oral glucose challenge: ≥140 but \<200 mg/dl
* HbA1c: ≥5.7 but \<6.4 %

MAO-type 2 diabetes group:

* BMI ≥30.0 but \<45.0 kg/m2
* clinical diagnosis of type 2 diabetes or fasting blood glucose concentration \>126 mg/dl or blood glucose concentration 2 h after a 75 g oral glucose challenge\>200 mg/dl or HbA1c \>6.4 % without medication if not diagnosed and medically treated for diabetes

Exclusion Criteria:

\- Individuals that do not meet all inclusion Criterion

Where it's running

• University of Missouri School of Medicine
  Columbia, Missouri, United States Recruiting

Study contacts

• Principal investigator: Bettina Mittendorfer — University of Missouri-Columbia
• Study coordinator: Heather McHatton
• Email: heathermchatton@health.missouri.edu
• Phone: (573) 882-7619

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Survey to determine eligibility for cardiovascular and obesity clinical trials

  This study is trying to see if people with heart issues or obesity can join new clinical trials by having them fill out a survey and undergo some health checks.

  Recruiting Brooklyn Clinical Research · Brooklyn, New York · NCT06412536

• Nutrition therapy program for obesity and diabetes in low-income individuals

  This study tests a special meal replacement program to see if it helps low-income people with obesity and diabetes lose weight and manage their blood sugar better.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT05799222

• Understanding how obesity affects insulin resistance through diet and molecular profiling

  This study is trying to see how different diets can affect insulin resistance in people with obesity by looking at changes in their body and blood over 12 weeks.

  Recruiting Stanford University · Stanford, California · NCT05165706

• Understanding how genetics affect response to GLP1R agonists in obesity and diabetes

  This study is testing how genetics affect the way overweight or obese people from the Old Order Amish community respond to the diabetes medication semaglutide.

  Recruiting Phase 1 University of Maryland, Baltimore · Lancaster, Pennsylvania · NCT05071898

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.